Skip to content
Open access · CC-BY via OpenAlex

Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease

Ahmed M. Moustafa, Weizhong Li, Ericka L. Anderson, Emily Wong, Parambir Singh Dulai, William J. Sandborn, William Biggs, Shibu Yooseph, Marcus B. Jones, Craig J. Venter, Karen E Nelson, John T. Chang, Amalio Telenti, Brigid Sweeney Boland

Clinical and Translational Gastroenterology · 2018 · ▲ 116 citations

Abstract

OBJECTIVES: Inflammatory bowel diseases (IBD), comprised of Crohn's disease (CD) and ulcerative colitis (UC), are characterized by a complex pathophysiology that is thought to result from an aberrant immune response to a dysbiotic luminal microbiota in genetically susceptible individuals. New technologies support the joint assessment of host-microbiome interaction. METHODS: Using whole genome sequencing and shotgun metagenomics, we studied the clinical features, host genome, and stool microbial metagenome of 85 IBD patients, and compared the results to 146 control individuals. Genetic risk scores, computed on 159 single nucleotide variants, and human leukocyte antigen (HLA) types differentiated IBD patients from healthy controls. RESULTS: Genetic risk was associated with the need for use of biologics in IBD and, modestly, with the composition of the gut microbiome. As compared with healthy controls, IBD patients had hallmarks of stool microbiome dysbiosis, with loss of a diversified core microbiome, enrichment and depletion of specific bacteria, and enrichment of bacterial virulence factors. CONCLUSIONS: We show that genetic risk may have a role in early risk stratification in the care of IBD patients and propose that expression of virulence factors in a dysbiotic microbiome may contribute to pathogenesis in IBD.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1038/ctg.2017.58
Canonical
link ↗
Fetched
2026-11-12 MST

Cite this

APA
Moustafa, A.M., Li, W., Anderson, E.L., Wong, E., Dulai, P.S., Sandborn, W.J., Biggs, W., Yooseph, S., Jones, M.B., Venter, C.J., Nelson, K.E., Chang, J.T., Telenti, A., &amp; Boland, B.S. (2018). Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease. <em>Clinical and Translational Gastroenterology</em>. https://doi.org/10.1038/ctg.2017.58
Vancouver
Moustafa AM, Li W, Anderson EL, Wong E, Dulai PS, Sandborn WJ, et al. Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease. Clinical and Translational Gastroenterology. 2018. doi:10.1038/ctg.2017.58.
BibTeX
@article{ahmed2018Geneti, title = {Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease}, author = {Ahmed M. Moustafa and Weizhong Li and Ericka L. Anderson and Emily Wong and Parambir Singh Dulai and William J. Sandborn and William Biggs and Shibu Yooseph and Marcus B. Jones and Craig J. Venter and Karen E Nelson and John T. Chang and Amalio Telenti and Brigid Sweeney Boland}, journal = {Clinical and Translational Gastroenterology}, year = {2018}, doi = {10.1038/ctg.2017.58}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings